• Read more about A Novel and Personalized Method using Simulation for Predicting Effective Therapeutics for Waldenströms Macroglobulinemia

The concept of treatment personalization in cancer often means associating a drug with an actionable mutation.

• Read more about Personalized Therapy Design for MPN Using Predictive Simulation Methodology with In Vitro, Ex Vivo, and In Vivo Validation

Background: Currently approved therapies for myeloproliferative neoplasms (MPNs) are limited to cytoreductive agents such as hydroxyurea and the Jak1/2 inhibitor ruxolitinib.

• Read more about Therapy Personalization Using Predictive Simulation Approach with Ex Vivo Clinical Validations

The epitome of cancer treatment personalization is N=1 segmentation where a custom therapy is designed for every patient. 

• Read more about In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells

Statins are potent competitive inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (HMGCR), a rate-limiting enzyme in the mevalonate pathway (cholesterol synthesis or isoprenoid pathway;

• Read more about Predictive Simulation Approach for Designing Cancer Therapeutic Regimens with Novel Biological Mechanisms

Ursolic acid (UA) is a pentacyclic triterpene acid present in many plants, including apples, basil, cranberries, and rosemary.

• Read more about Predicting GBM response to targeted therapeutics using simulation with ex vivo validations

Background: The unique signature of a patient’s tumor implies that a one-size-fits-all treatment approach will likely fail. This necessitates a rationally designed personalized therapeutic approach employing N=1 segmentation.

• Read more about Predictive analysis of microenvironment impact on clinical outcomes to drug agents using simulation of myeloproliferative neoplasms

Background: The Jak2-V617F mutation is frequently found in MPN. The bone marrow micro-environment of MPN patients constitutes high levels of TNFα, IFNγ and IL-6.

• Read more about In silico modeling predicts drug sensitivity of patient-derived cancer cells

Glioblastoma (GBM) is an aggressive disease associated with poor survival.

• Read more about Individualized therapy identified using simulation for bortezomib resistant patient with ex vivo validation

Background: The unique signature of a patient’s tumor mandates the need to rationally design personalized therapies employing N=1 segmentation conceptually.

• Read more about A Predictive Model of an Oral Inflammatory Response

Recently, we developed an in silico simulation model to predict chemokine and cytokine responses of dendritic cells to pro-inflammatory stimulation.